Open Access

The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer

  • Yu-Jen Wang1,
  • Chao-Yuan Huang4,
  • Wei-Hsien Hou2,
  • Chia-Chun Wang2,
  • Keng-Hsueh Lan2,
  • Chung-Hsin Chen4,
  • Hong-Jen Yu4,
  • Ming-Kuen Lai4,
  • Ann-Lii Cheng3, 5,
  • Shihh-Ping Liu4,
  • Yeong-Shiau Pu4Email author and
  • Jason Chia-Hsien Cheng2, 5, 6Email author
World Journal of Surgical Oncology201513:312

https://doi.org/10.1186/s12957-015-0721-4

Received: 19 May 2015

Accepted: 22 October 2015

Published: 6 November 2015

Abstract

Background

The prognostic factors for the recurrence of lymph node (LN) metastasis after dose-escalated radiotherapy (RT) in prostate cancer patients have not been well investigated. We report the prognostic factors and outcomes in patients receiving salvage treatment for LN recurrence after high-dose intensity-modulated RT (IMRT).

Methods

We studied a cohort of 419 patients with localized prostate adenocarcinoma undergoing definitive IMRT (78 Gy). LN recurrence was diagnosed by size criteria using computed tomography (CT) or magnetic resonance imaging, or abnormal uptake of 18F-fluorocholine by LNs on positron emission tomography/CT. Overall survival and LN recurrence-free survival (LNRFS) were calculated, and prognostic factors were evaluated.

Results

With a median follow-up of 60 months, 18 patients (4.3 %) had LN recurrence and a significantly lower 5-year overall survival rate (60 vs. 90 %, p = 0.003). Univariate analysis showed that T3/T4 stage (p = 0.003), Gleason score >7 (p < 0.001), and estimated risk of pelvic LN involvement of >30 % by the Roach formula (p = 0.029) were associated with significantly lower LNRFS. On multivariate analysis, high Gleason score (hazard ratio = 5.99, p = 0.007) was the only independent factor. The 1/2-year overall survivals after LN recurrence were 67/54 %. Patients with isolated LN recurrence (p = 0.003), prostate-specific antigen (PSA) doubling time >5 months (p = 0.009), interval between PSA nadir and biochemical failure >12 months (p = 0.035), and PSA <10 ng/ml at LN recurrence (p = 0.003) had significantly better survival. Patients with isolated LN recurrence had significantly better survival when treated with combined RT and hormones than when treated with hormones alone (p = 0.011).

Conclusions

Gleason score of >7 may predict LN recurrence in prostate cancer patients treated with definitive IMRT. Small number of patients limits the extrapolation of this risk with the primary treatment strategy. Combined RT and hormones may prolong survival in patients with isolated LN recurrence.

Keywords

Prostate cancer Radiotherapy Lymph node Recurrence Prognosis

Background

Definitive radiotherapy (RT) is a first-line treatment for patients with localized prostate cancer (PCa) [1, 2]. Dose-escalated intensity-modulated radiation therapy (IMRT) has been increasingly used in clinical practice for PCa [3] and results in satisfactory outcomes and acceptable toxicity [46]. Compared with three-dimensional conformal radiation therapy, IMRT permits delivery of higher radiation dose while reducing the risk of gastrointestinal toxicity [79]. Most dose-escalated radiotherapies are designed to treat the prostate and seminal vesicles but not the pelvic lymphatics. Although prophylactic irradiation of lymph nodes has long been recommended for head and neck cancer, rectal cancer, anal cancer, breast cancer, and certain solid tumors, the therapeutic ratio of whole pelvic RT remains unknown for PCa. Randomized trials have failed to provide solid evidence for the survival benefit of additional RT to the pelvic lymphatics [1012].

The lymph node is the second most common metastatic site in prostate cancer [13]. The nomogram to predict lymph node involvement for prostate cancer was developed using known prognostic factors, including pretreatment prostate-specific antigen (PSA), Gleason score, and clinical stage as the key factors for estimating the risk of lymph node metastasis [14, 15]. Although the percentage of lymph node metastasis is low in PCa patients undergoing radical prostatectomy, lymph node dissection is known to prolong their survival [16, 17]. However, the prognostic factors that predict the recurrence of lymph node metastasis in PCa patients (after definitive RT directed only to prostate and seminal vesicles) has not been well investigated.

For PCa patients with lymph node recurrence, androgen deprivation therapy (ADT) is the treatment of choice [1, 2]. The outcomes for PCa patients with lymph node metastasis vary between studies. Some studies report relatively good outcome in patients with lymph node recurrence receiving aggressive salvage treatment [1820]. In accordance with a trial of dose-escalated RT at our institution, we have been using definitive IMRT (78 Gy) for PCa patients since 2003, targeting only the prostate and involved seminal vesicles. In this study, our aim was to determine the factors predicting treatment failure by investigating the characteristics of patients with lymph node recurrence after definitive RT without elective pelvic node irradiation and their outcomes with salvage treatment.

Methods

Patients and diagnostic criteria for lymph node metastasis

The cohort consisted of 419 Asian patients with non-metastatic prostate adenocarcinoma treated in our institute from December 2003 to December 2010. The study has been approved by the ethical committees related to the institution in which it was performed, and patients gave informed consent to the study. All patients underwent initial treatment with either step-and-shoot IMRT, tomotherapy, or volumetric modulated arc therapy. In all patients, the RT dose was 78 Gy in 39 fractions, and the clinical target volume (CTV) consisted of the prostate and the involved seminal vesicle(s) but not the pelvic lymph nodes. The initial treatment with ADT was left to the discretion of the prescribing physicians. ADT was administered neoadjuvantly more than 2 months prior to RT and continued concurrently with RT. Alternatively, maintenance ADT was administered concurrently with RT and was continued after RT. Patients typically received gonadotropin-releasing hormone (GnRH) agonist as monotherapy. An oral anti-androgen was usually initiated at the start of GnRH agonist therapy to prevent a rebound surge of androgen.

Biochemical failure after the primary RT was defined according to the Phoenix definition (PSA elevation exceeding PSA nadir by 2 ng/ml). The diagnosis of lymph node metastasis was based on the following criteria: the short-axis diameter of the lymph node was elongated and exceeded 10 mm or was rounded and exceeded 8 mm on computed tomography (CT) or magnetic resonance imaging (MRI) or abnormal uptake by lymph nodes of 18F-fluorocholine on positron emission tomography (PET)/CT. PSA doubling time was defined as the time interval needed for serum PSA levels to increase by 100 %. The PSA nadir–biochemical failure interval was defined as the interval between the lowest PSA level and the diagnosis of biochemical failure.

Follow-up and toxicity related to salvage treatment

Follow-up duration, survival time, and event time were calculated from the start of the initial IMRT for the comparison between patients with and without lymph node recurrence and from the start of salvage treatment only for patients with lymph node recurrence. Kaplan-Meier analysis was performed to determine overall survival and lymph node recurrence-free survival rates. Treatment-related toxicities were determined using Common Toxicity Criteria v.4.0.

Statistical analysis

Descriptive analysis was performed by calculating ranges, means, medians, and standard deviations. Continuous variables were compared with a two-sided unpaired t test. Chi-square and Fisher’s exact tests were used for contingency table analysis. The log-rank test was used to determine prognostic factors affecting survival. All prognostic variables found to be significant or borderline significant in univariate analysis were included in multivariate analysis using the Cox proportional hazards regression model. Significance was assumed if p < 0.05. All statistics were done with PASW Statistics 18 (IBM Corp., Armonk, NY, USA).

Results

Differences in characteristics between patients with and without lymph node recurrence

With a median follow-up of 60 months, 18 of 419 patients (4.3 %) had lymph node recurrence. Of these 18 patients, 3 patients had initial T1, 4 had T2, 9 had T3, and 2 had T4 disease. Eleven patients (61.1 %) had a Gleason score of 8 or higher. The median value of initial PSA was 18.4 ng/ml (range 4.8–101.5). Sixteen patients (88.8 %) had high risk or very high risk of PCa according to the National Comprehensive Cancer Network (NCCN) classification. Their characteristics are shown in Table 1.
Table 1

Patient/tumor characteristics and the use of androgen deprivation therapy (ADT) between patients without (n = 401) and with (n = 18) lymph node (LN) recurrence

Variable

Without LN

With LN

Number (%)

Number (%)

Age

 

 <70

134 (33.4)

5 (27.7)

 ≥70

267 (66.6)

13 (72.3)

T stage

 

 1a

5 (1.2)

0 (0)

 1b

6 (1.5)

0 (0)

 1c

124 (30.9)

3 (16.7)

 2a

52 (13.0)

1 (5.6)

 2b

40 (10.0)

3 (16.7)

 2c

42 (10.5)

0 (0)

 3a

72 (18.0)

2 (11.1)

 3b

53 (13.2)

7 (38.9)

 4

7 (1.7)

2 (11.1)

Gleason score

 

 <7

125 (31.2)

3 (16.7)

 7

185 (46.1)

4 (22.2)

 8–10

91 (22.7)

11 (61.1)

PSA (ng/ml)

 

 <10

117 (29.2)

4 (22.2)

 10–20

119 (29.7)

5 (27.7)

 ≥20

165 (41.1)

9 (50.0)

Risk group

 

 Low

41 (10.2)

1 (5.6)

 Intermediate

121 (30.2)

1 (5.6)

 High

180 (44.9)

7 (38.9)

 Very high

59 (14.7)

9 (50.0)

Any ADT

 No

57 (14.2)

2 (11.1)

 Yes

344 (85.8)

16 (88.9)

Neoadjuvant ADT

 No

127 (31.7)

4 (22.2)

 Yes

274 (68.3)

14 (77.8)

Concurrent ADT

 No

103 (25.7)

8 (44.4)

 Yes

298 (74.3)

10 (55.6)

Maintenance ADT

 No

177 (44.1)

9 (50.0)

 Yes

224 (55.9)

9 (50.0)

As shown in Fig. 1, the 5-year overall survival rate was significantly lower in patients with lymph node recurrence (60 vs. 90 %, p = 0.003). Univariate analysis identified advanced T stage (T3/T4 vs. T1/T2) (p = 0.003), high Gleason score (>7 vs. ≤7) (p < 0.001), and the estimated risk of pelvic lymph node involvement by the Roach formula of more than 30 % (p = 0.029) as factors associated with higher risk of lymph node recurrence. On multivariate analysis, high Gleason score (hazard ratio = 5.99, p = 0.007) was the only independent prognostic factor for lymph node recurrence, while advanced T stage was of borderline significance (hazard ratio = 2.68, p = 0.074) (Table 2).
Fig. 1

Kaplan-Meier analyses of overall survival of 419 prostate cancer patients without (401 patients) and with (18 patients) lymph node (LN) recurrence

Table 2

Univariate and multivariate analyses of the prognostic factors on lymph node recurrence-free survival

Variable

5-year lymph node recurrence-free rate (%)

p value

HR (95 % CI)

p value

Age

 ≥70

96

0.972

  

 <70

97

   

T stage

 T3–T4

93

0.003

2.68 (0.91–7.90)

0.074

 T1–T2

98

   

Gleason score

 8–10

98

<0.001

5.99 (1.62–22.14)

0.007

 ≤7

90

   

PSA (ng/ml)

 ≥30

94

0.100

1.26 (0.33–4.82)

0.74

 <30

97

   

RFLN (%)

 >30

93

0.029

0.51 (0.10–2.60)

0.419

 <30

98

   

ADT

 Yes

96

0.732

  

 No

96

   

ADT Androgen deprivation therapy, CI confidence interval, HR hazard ratio, RFLN Roach formula for the risk of pelvic lymph node metastasis

Salvage treatment in patients with lymph node recurrence

Of the 18 patients with lymph node recurrence, 13 patients had isolated lymph node recurrence, defined as any recurrence at nodal regions without other distant metastasis. Eight patients had pelvic lymph node recurrence alone (N1); 2 had simultaneous pelvic and para-aortic lymph node recurrences (M1a); and 3 had neck, axilla, and anterior mediastinum lymph node recurrences (M1a). The median time from primary radiation therapy to biochemical failure was 36 months (range 15–99). Recurrence in 9 patients was diagnosed by both 18F-fluorocholine PET/CT and MRI, 8 by CT and 1 by MRI. At the diagnosis of lymph node recurrence, the median age was 71.5 years, the median PSA level was 20.0 ng/ml (range 2.0–680), and the median PSA nadir-failure interval was 16.7 months (range 5.9–76.2). All patients with lymph node recurrence received salvage hormone treatment. Of the 13 patients with isolated lymph node recurrence, 6 patients underwent additional RT with a median dose of 55 Gy (range 55–63) to the involved lymph nodes. All 6 patients had a normal PSA level after salvage RT for a median of 17 months. One patient with isolated lymph node recurrence underwent salvage pelvic lymph node dissection, had a second biochemical failure, and received salvage RT resulting in PSA control. Six patients with isolated lymph node recurrence received hormone therapy alone, with 4 of them experiencing disease progression. One of them with initial pelvic lymph node recurrence had subsequent para-aortic lymph node recurrence and received additional salvage RT.

Survivals and prognostic factors after salvage treatment for lymph node recurrence

With a median follow-up of 12 months from the salvage treatment, 7 patients died, with 6 of them due to prostate cancer. Relapse of lymph node metastasis occurred after treatment in one patient and subsequently to other lymph nodes in 11 patients; 5 patients had bone metastasis. The 1- and 2-year overall survival rates after lymph node recurrence were 67 and 54 %, respectively, with a median survival of 12.3 months. None of the 18 patients had more than grade 2 toxicity related to the salvage treatments. Patients with isolated lymph node recurrence (p = 0.003), PSA doubling time >5 months (p = 0.009), PSA nadir-to-biochemical failure interval >12 months (p = 0.035), and PSA <10 ng/ml at the diagnosis of lymph node recurrence (p = 0.003) had significantly better overall survival. On multivariate analysis, none of these prognosticators proved to be of significance (Table 3).
Table 3

Univariate and multivariate analyses of the prognostic factors on overall survival after lymph node recurrence

 

2-year survival rate (%)

p value

HR (95 % CI)

p value

Age

 ≥70

41

0.160

  

v<70

80

   

T stage

 T3–T4

37

0.236

  

 T1–T2

100

   

Gleason score

 8–10

47

0.661

  

 ≤7

63

   

PSA (ng/ml)

 ≥20

50

0.762

  

 <20

58

   

Isolated lymph node recurrence

 Yes

67

0.003

5.22 (0.50–55.03)

0.169

 No

0

   

PSA doubling time

 >5 months

89

0.009

1.869 (0.05–74.19)

0.739

 <5 months

17

   

PSA nadir-free interval

 >12 months

80

0.035

1.203 (0.09–15.62)

0.888

 <12 months

20

   

PSA at lymph node recurrence (ng/ml)

 >10

19

0.003

510,993 (0–1.22E184)

0.950

 <10

100

   

ADT Androgen deprivation therapy, HR hazard ratio, CI confidence interval

Patients with isolated lymph node recurrence treated with combined RT and hormone therapy

We compared the survival rates between patients with isolated lymph node recurrence (13 patients) and with simultaneous lymph node recurrence and distant metastasis (5 patients). The 1- and 2-year survival rates were 83/67 and 0/0 % (p = 0.003), respectively (Fig. 2). For the 13 patients with isolated lymph node recurrence treated with combined RT and hormone therapy (7 patients) or hormonal therapy alone (6 patients), the 1- and 2-year survival rates were 100/100 % (median survival 25.8 months) and 60/0 % (median survival 9.0 months), respectively (p = 0.011) (Fig. 3).
Fig. 2

Kaplan-Meier analyses of overall survival of 18 prostate cancer patients with isolated lymph node recurrence (ILR) (13 patients) and with simultaneous LN recurrence and distant metastasis (5 patients)

Fig. 3

Kaplan-Meier analyses of overall survival of 13 prostate cancer patients with exclusive lymph node recurrence treated with combined radiotherapy and hormone therapy (RT + HT) (seven patients) or hormonal therapy alone (HT) (six patients)

Discussion

Little is known about the risk factors of lymph node recurrence in PCa patients after definitive RT as well as their outcome and prognosis after salvage treatment for nodal recurrence, especially in the era of dose-escalated RT. Our current study is the first to focus on the lymph node recurrence in PCa patients undergoing the 78-Gy IMRT to the prostate and involved seminal vesicles but not the pelvic nodes. We identified not only characteristics associated with lymph node recurrence but also the prognostic factors determining outcome in patients with nodal recurrence treated by salvage treatment. Moreover, we showed that RT combined with hormones had great therapeutic value in patients with isolated lymph node recurrence.

Lymph node metastasis, though infrequent, has been recognized as a negative prognostic factor of PCa, and its risk of occurrence has been associated certain tumor characteristics. In our series, the 5-year overall survival rate was significantly lower in patients with lymph node recurrence. Previous studies have investigated the probability of pelvic lymph node involvement using the established predictive nomogram [14, 15]. Gleason sum and PSA level were found to predict the risk of lymph node involvement for post-prostatectomy patients [15]. Our study (which excluded patients receiving elective pelvic node irradiation) similarly identified Gleason sum as the only independent factor associated with lymph node recurrence. In contrast, the usefulness of the Roach formula as a tool for predicting lymph node metastasis in contemporary patients is debatable [21, 22]. With bowel-related quality of life being better in PCa patients receiving prostate-only RT than whole-pelvis RT [23], the role of prophylactic lymphatic RT remains unsettled. For the high-risk PCa patients, questions about the effects of pelvic nodal irradiation are being addressed by the ongoing clinical trial (RTOG 0924) [24].

Of note, both N1 and M1a in the current staging system are referred to as lymph node metastasis and may infer a diversity of outcomes. The salvage treatments and survival rates of PCa patients with lymph node recurrence were very heterogeneous [25, 26]. Therefore, prognostic factors predictive of lymph node recurrence would be expected to help doctors tailor treatment to achieve the best possible outcome. Pond et al. reported that median survival was longest in patients with lymph node-only disease (26.7 months), followed by bone-only and bone-plus-node disease [25]. Yossepowitch et al. found that longer PSA doubling time is a favorable prognostic factor in post-prostatectomy patients [26]. Moreover, our univariate analysis identified isolated lymph node recurrence, PSA nadir-to-biochemical failure interval, and PSA level at the diagnosis of lymph node recurrence, in addition to PSA doubling time, as significant prognostic factors. Modern imaging tools, such as 18F-fluorocholine PET/CT, have increased the detectability of small and otherwise undetectable lymph node metastases and thus may increase PCa prevalence at even lower PSA levels [2729].

Salvage ADT was given to all our patients as the suggested treatment guideline [2]. Nevertheless, ADT is not a curative treatment, with most treated patients ultimately developing castration-resistant disease [30]. Two studies used an advanced RT technique (stereotactic body radiation therapy) as a salvage modality and achieved safe and effective local control [18, 31], while other studies performed salvage lymph node dissection and obtained a certain degree of biochemical response [20, 32]. Additionally, adjuvant RT had a beneficial impact on survival in pN1 PCa patients with low-volume intermediate-/high-grade nodal disease and intermediate-volume nodal disease [33]. Metastasis-directed therapy was recommended as a promising approach with acceptable toxicity for PCa patients with oligometastasis, mostly with lymph node metastasis [34]. With isolated LN recurrence representing limited volume of disease, our series similarly showed that combining RT and hormones (rather than treating with hormones alone) significantly increased survival. The 2-year survival rate of 100 % and the median survival of 25.8 months were encouraging for this select group of patients treated with combined modalities including local RT and systemic hormones.

Unlike surgery, which usually provide nodal dissection along with radical prostatectomy, RT is more commonly delivered to prostate and seminal vesicles only. The difference in primary nodal treatment between the two modalities is reflected in the outcomes of patients with lymph node metastasis. The 5-year survival rate of 96 % was shown in a Chinese series of PCa patients with lymph node metastasis on radical prostatectomy [35], compared with 60 % in our patients treated by node-sparing RT. However, the small number of patients (18) and the low crude rate (4.3 %) of lymph node metastasis from the whole group in this study limit the extrapolation of the risk of lymph node metastasis with the primary treatment strategy including pelvic RT. Besides RT, hormonal therapy has been the effective treatment to improve the survival outcomes of PCa patients with adverse characteristics, such as high Gleason score [36].

Our series has limitations. First of all, our data included only a small number of patients with lymph node recurrence, even after a long follow-up period. The small patient number was likely to be the reason that no significant prognostic factor was identified on multivariate analysis of survival after lymph node recurrence. Ideally, this limitation might be solved by future multi-center studies. Secondly, the retrospective nature of the study and the uncontrolled use of hormone therapy in the primary treatment might bias estimates of the true prevalence of lymph node recurrence. Finally, the heterogeneity of salvage treatments given after the lymph node recurrence unavoidably confounded the prognosis. Further prospective study with longer follow-up time is needed.

Conclusions

In conclusion, our data of PCa patients treated with definitive IMRT and not elective pelvic node irradiation indicated the significant association of high Gleason score with lymph node recurrence. Isolated lymph node recurrence, PSA doubling time of >5 months, PSA nadir-to-biochemical failure interval of >12 months, and PSA of <10 ng/ml at the diagnosis of lymph node recurrence were the factors associated with better overall survival after biochemical failure. For patients with isolated LN recurrence, the combined use of RT to the involved nodes and hormones resulted in the longer survival.

Declarations

Acknowledgement

The authors thank Dr. Jo-Ting Tsai of the Department of Radiation Oncology, Taipei Medical University-Shuang Ho Hospital, for her generous encouragement.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Radiation Oncology, Taipei Medical University-Shuang Ho Hospital
(2)
Division of Radiation Oncology, College of Medicine and Hospital, National Taiwan University
(3)
Departments of Oncology, College of Medicine and Hospital, National Taiwan University
(4)
Departments of Urology, College of Medicine and Hospital, National Taiwan University
(5)
Graduate Institutes of Oncology, College of Medicine, National Taiwan University
(6)
Clinical Medicine, College of Medicine, National Taiwan University

References

  1. Droz J-P, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. The Lancet Oncology. 2014;15:e404–14.View ArticlePubMedGoogle Scholar
  2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.View ArticlePubMedGoogle Scholar
  3. Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309:2587–95.View ArticlePubMedGoogle Scholar
  4. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85:686–92.View ArticlePubMedGoogle Scholar
  5. Teh BS, Mai W-Y, Uhl BM, Augspurger ME, Grant WH, Lu HH, et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: acute toxicity and dose–volume analysis. Int J Radiat Oncol Biol Phys. 2001;49:705–12.View ArticlePubMedGoogle Scholar
  6. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–6.View ArticlePubMedGoogle Scholar
  7. Goldin GH, Sheets NC, Meyer A-M, Kuo T-M, Wu Y, Stürmer T, et al. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Internal Medicine. 2013;173:1136–43.View ArticlePubMedGoogle Scholar
  8. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–9.View ArticlePubMedGoogle Scholar
  9. Wolff D, Stieler F, Welzel G, Lorenz F, Abo-Madyan Y, Mai S, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226–33.View ArticlePubMedGoogle Scholar
  10. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;66:647–53.View ArticlePubMedGoogle Scholar
  11. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–73.View ArticlePubMedGoogle Scholar
  12. Morikawa LK, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011;80:6–16.View ArticlePubMedGoogle Scholar
  13. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: a population based analysis. Prostate. 2014;74:210–6.View ArticlePubMedGoogle Scholar
  14. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798–803.View ArticlePubMedGoogle Scholar
  15. Roach M, Marquez C, Yuo H-S, Narayan P, Coleman L, Nseyo UO, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33–7.View ArticlePubMedGoogle Scholar
  16. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172:2252–5.View ArticlePubMedGoogle Scholar
  17. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178:864–71.View ArticlePubMedGoogle Scholar
  18. Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clinical Genitourinary Cancer. 2015;13:e279.View ArticlePubMedGoogle Scholar
  19. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299–309.View ArticlePubMedGoogle Scholar
  20. Tilki D, Mandel P, Seeliger F, Kretschmer A, Karl A, Ergün S, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol. 2015;193:484–90.View ArticlePubMedGoogle Scholar
  21. Goldner G, Dimopoulos J, Pötter R. Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy? Radiother Oncol. 2010;94:324–7.View ArticlePubMedGoogle Scholar
  22. Rahman S, Cosmatos H, Dave G, Williams S, Tome M. Predicting pelvic lymph node involvement in current-era prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:906–10.View ArticlePubMedGoogle Scholar
  23. Kaidar-Person O, Roach M, Créhange G. Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: a step forward. Int J Radiat Oncol Biol Phys. 2013;86:600–5.View ArticlePubMedGoogle Scholar
  24. Pinkawa M, Piroth MD, Holy R, Fischedick K, Klotz J, Székely-Orbán D, et al. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison. Int J Radiat Oncol Biol Phys. 2011;81:23–8.View ArticlePubMedGoogle Scholar
  25. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3–6.View ArticlePubMedGoogle Scholar
  26. Yossepowitch O, Bianco FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007;51:940–8.PubMed CentralView ArticlePubMedGoogle Scholar
  27. Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, et al. Does choline PET/CT change the management of prostate cancer patients with biochemical failure? Am J Clin Oncol. 2014;90:448. doi org/101097/COC.Google Scholar
  28. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–9.View ArticlePubMedGoogle Scholar
  29. Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T, et al. Detection of lymph node metastasis in patients with nodal prostate cancer relapse using 18F/11 C-choline positron emission tomography/computerized tomography. J Urol. 2014;192:103–11.View ArticlePubMedGoogle Scholar
  30. Karantanos T, Corn P, Thompson T. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501–11.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:889–97.View ArticlePubMedGoogle Scholar
  32. Jilg C, Rischke H, Reske S, Henne K, Grosu A-L, Weber W, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012;188:2190–7.View ArticlePubMedGoogle Scholar
  33. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014;32:3939–47.View ArticlePubMedGoogle Scholar
  34. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2014;67:852–63.View ArticlePubMedGoogle Scholar
  35. Qin X, Han C, Zhang H, Dai B, Zhu Y, Shen Y, et al. Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study. World J Surg Oncol. 2015;13:172.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Hu J, Xu H, Zhu W, Wu F, Wang J, Ding Q, et al. Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5194 patients. World J Surg Oncol. 2015;13:73.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Wang et al. 2015

Advertisement